MBX Biosciences (MBX) Consolidated Net Income (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Consolidated Net Income data on file, last reported at -$102.0 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 277.35% year-over-year to -$102.0 million; the trailing twelve-month figure through Mar 2026 stood at -$213.7 million (down 181.93% YoY), and the FY2025 full-year result was -$184.7 million, down 78.69% from the prior year.
• Consolidated Net Income slipped to -$102.0 million in Q1 2026, from -$14.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$10.9 million in Q3 2023 to a low of -$102.0 million in Q1 2026.
• A 4-year average of -$29.8 million and a median of -$16.8 million in 2024 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income increased 13.78% in 2024 and sank 277.35% in 2026, its largest moves.
• Tracing MBX's Consolidated Net Income over 4 years: stood at -$14.5 million in 2023, then gained by 13.78% to -$12.5 million in 2024, then declined by 19.43% to -$14.9 million in 2025, then tumbled by 584.29% to -$102.0 million in 2026.
• Business Quant data shows MBX's Consolidated Net Income at -$102.0 million in Q1 2026, -$14.9 million in Q4 2025, and -$61.9 million in Q3 2025.